Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - 16 April 2019 (1)

Overview

The Therapeutic Goods Act 1989 was enacted to establish a comprehensive regulatory framework for the quality, safety, efficacy, and timely availability of therapeutic goods in Australia. This legislation was introduced to address the need for stringent control over the manufacture, supply, and advertising of therapeutic goods, ensuring they meet nationally recognised standards and are safe for public use. The Act is overseen by the Therapeutic Goods Administration, a department under the Commonwealth of Australia's Department of Health, with a policy objective to protect public health by ensuring therapeutic goods are of high quality and do not pose unnecessary risks to health and safety. The Act empowers the Secretary to issue licences to manufacturers, thereby allowing only those entities meeting specified standards to manufacture therapeutic goods, thus maintaining a high standard of healthcare provision in the country.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, ensuring the safety, quality, and efficacy of these products. This Act applies to a wide range of entities, including individuals and corporations, engaged in the manufacture, importation, supply, and advertising of therapeutic goods. The Act covers various therapeutic goods, such as medicines, medical devices, blood, and tissues. The jurisdiction of the Act extends across the Commonwealth of Australia, including all states and territories, ensuring a unified regulatory approach. Notably, the Act provides certain exemptions and exclusions, such as for goods intended for personal use or research purposes. The application of the Act can be further extended or restricted through subordinate instruments, allowing the Therapeutic Goods Administration to adapt the regulatory framework to emerging needs and developments. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods, as seen in the case of Nestle Australia Ltd and Tasmanian Botanics Pty Ltd, is an example of the practical implementation of this legislative framework.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") encompasses various provisions to ensure the safety, quality, and efficacy of therapeutic goods in Australia. In the specific instance detailed in the gazetted notice, the Secretary has granted licences to certain entities for the manufacture of therapeutic goods (section 38). The licence numbers and corresponding entities include Nestle Australia Ltd with Licence No. MI-2018-LI-07733-1 for their facility at 1585 Sydney Road, Campbellfield, VIC, 3061, and Licence No. MI-2018-LI-07244-1 for their facility at 254-294 Wellington Road, Mulgrave, VIC, 3170, as well as Tasmanian Botanics Pty Ltd with Licence No. MI-2017-LI-00008-1 for their facility at 12 Rifle Range Road, Pontville, TAS, 7030. These licences authorize the respective entities to manufacture therapeutic goods in accordance with the conditions set out in the Act. Entities granted a manufacturing licence under the Therapeutic Goods Act 1989 are required to adhere to stringent quality and safety standards. This includes, but is not limited to, maintaining proper records, ensuring that all manufacturing processes comply with Good Manufacturing Practice (GMP) guidelines, and ensuring that therapeutic goods produced meet the standards specified in the Australian Register of Therapeutic Goods (ARTG). The licensees must also ensure that any changes to their manufacturing processes or facilities are reported to and approved by the Therapeutic Goods Administration (TGA) before implementation. Failure to comply with the requirements set out in the Therapeutic Goods Act 1989 or the conditions of the manufacturing licence can result in significant legal consequences. The Act provides for both civil and criminal penalties for breaches. Civil penalties may include fines up to a substantial amount, determined by the severity and frequency of the breach. In more serious cases, criminal penalties may apply, including fines and imprisonment for directors or officers of the company. Additionally, the TGA has the authority to suspend or cancel a manufacturing licence if a serious breach is identified, which can have severe ramifications for the entity's ability to operate within the Australian market.